Skip to main content
. 2022 Jul 15;29(7):4970–4980. doi: 10.3390/curroncol29070395

Figure 6.

Figure 6

Figure 6

Participant preferences: (a) How do you manage treatment in a patient with myelofibrosis (MF) on stable doses of ruxolitinib who has an intercurrent bacterial infectious event? (b) How do you manage treatment in a patient with MF on stable doses of ruxolitinib who has a first episode of herpes zoster reactivation or (c) who has two or more episodes of herpes zoster reactivation?